Abstract
Positron emission tomography, an imaging tool using radiolabeled tracers in humans and preclinical species, has been widely used in recent years in drug development, particularly in the central nervous system. One important goal of PET in drug development is assessing the occupancy of various molecular targets (e.g., receptors, transporters, enzymes) by exogenous drugs. The current linear mathematical approaches used to determine occupancy using PET imaging experiments are presented. These algorithms use results from multiple regions with different target content in two scans, a baseline (pre-drug) scan and a post-drug scan. New mathematical estimation approaches to determine target occupancy, using maximum likelihood, are presented. A major challenge in these methods is the proper definition of the covariance matrix of the regional binding measures, accounting for different variance of the individual regional measures and their nonzero covariance, factors that have been ignored by conventional methods. The novel methods are compared to standard methods using simulation and real human occupancy data. The simulation data showed the expected reduction in variance and bias using the proper maximum likelihood methods, when the assumptions of the estimation method matched those in simulation. Between-method differences for data from human occupancy studies were less obvious, in part due to small dataset sizes. These maximum likelihood methods form the basis for development of improved PET covariance models, in order to minimize bias and variance in PET occupancy studies.
Similar content being viewed by others
References
Abanades S et al (2011) Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. J Cereb Blood Flow Metab 31:944–952. https://doi.org/10.1038/jcbfm.2010.175
Carson RE (2000) PET physiological measurements using constant infusion. Nucl Med Biol 27:657–660
Carson RE (2003) Tracer kinetic modeling. In: Valk PE, Bailey DL, Townsend DW, Maisey MN (eds) Positron emission tomography: basic science and clinical practice. Springer, London, pp 147–179
Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, Herscovitch P (1993) Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13:24–42. https://doi.org/10.1038/jcbfm.1993.6
Castner SA et al (2014) Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates. Neuropsychopharmacology. https://doi.org/10.1038/npp.2014.4
Chen KW, Huang SC, Yu DC (1991) The effects of measurement errors in the plasma radioactivity curve on parameter estimation in positron emission tomography. Phys Med Biol 36:1183–1200
Cobelli C, Foster D, Toffolo G (2001) Tracer kinetics in biomedical research: from data to model. Plenum Publishing, New York
Cosgrove KP et al (2011) Assessing the sensitivity of [(1)(1)C]p943, a novel 5-HT1B radioligand, to endogenous serotonin release. Synapse 65:1113–1117. https://doi.org/10.1002/syn.20942
Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN (2010) Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 30:46–50. https://doi.org/10.1038/jcbfm.2009.190
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185
Esterlis I et al (2013) Imaging changes in synaptic acetylcholine availability in living human subjects. J Nucl Med 54:78–82. https://doi.org/10.2967/jnumed.112.111922
Finnema SJ et al (2016) Imaging synaptic density in the living human brain. Sci Transl Med 8:348–396
Gallezot JD et al (2011) Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. NeuroImage 56:268–279. https://doi.org/10.1016/j.neuroimage.2010.09.040
Gallezot JD et al (2012) Affinity and selectivity of [(1)(1)C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 66:489–500. https://doi.org/10.1002/syn.21535
Gallezot JD et al (2017) Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. J Cereb Blood Flow Metab 37:1095–1107. https://doi.org/10.1177/0271678x16650697
Gunn RN, Gunn SR, Cunningham VJ (2001) Positron emission tomography compartmental models. J Cereb Blood Flow Metab 21:635–652. https://doi.org/10.1097/00004647-200106000-00002
Hillmer AT et al (2016) PET imaging evaluation of [(18)F]DBT-10, a novel radioligand specific to alpha7 nicotinic acetylcholine receptors, in nonhuman primates. Eur J Nucl Med Mol Imaging 43:537–547. https://doi.org/10.1007/s00259-015-3209-0
Huesman RH, Mazoyer BM (1987) Kinetic data analysis with a noisy input function. Phys Med Biol 32:1569–1579
Ichise M et al (2003) Linearized reference tissue parametric imaging methods: application to [\(^{11}\)C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096–1112. https://doi.org/10.1097/01.WCB.0000085441.37552.CA
Ichise M, Toyama H, Innis RB, Carson RE (2002) Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 22:1271–1281. https://doi.org/10.1097/00004647-200210000-00015
Innis RB et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539. https://doi.org/10.1038/sj.jcbfm.9600493
Jacquez JA (1985) Compartmental analysis in biology and medicine, 2nd edn. University of Michigan Press, Ann Arbor
Joshi AD et al (2015) Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans. Synapse 69:33–40. https://doi.org/10.1002/syn.21782
Kim SJ et al (2013) Determination of the in vivo selectivity of a new kappa-opioid receptor antagonist PET tracer 11C-LY2795050 in the rhesus monkey. J Nucl Med 54:1668–1674. https://doi.org/10.2967/jnumed.112.118877
Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158. https://doi.org/10.1006/nimg.1996.0066
Li R, Barton HA, Yates PD, Ghosh A, Wolford AC, Riccardi KA, Maurer TS (2014) A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling. J Pharmacokinet Pharmacodyn 41:197–209. https://doi.org/10.1007/s10928-014-9357-1
Logan J et al (1990a) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740–747. https://doi.org/10.1038/jcbfm.1990.127
Logan J et al (1990b) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740–747. https://doi.org/10.1038/jcbfm.1990.127
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834–840. https://doi.org/10.1097/00004647-199609000-00008
Nabulsi NB et al (2016) Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain. J Nucl Med 57:777–784. https://doi.org/10.2967/jnumed.115.168179
Nabulsi NB, Zheng MQ, Ropchan J, Labaree D, Ding YS, Blumberg L, Huang Y (2011) [\(^{11}\)C]GR103545: novel one-pot radiosynthesis with high specific activity. Nucl Med Biol 38:215–221. https://doi.org/10.1016/j.nucmedbio.2010.08.014
Naganawa M et al (2014) Evaluation of the agonist PET radioligand [(1)(1)C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242. NeuroImage 99:69–79. https://doi.org/10.1016/j.neuroimage.2014.05.033
Naganawa M et al (2015) Test–retest reproducibility of binding parameters in humans with \(^{11}\)C-LY2795050, an antagonist PET radiotracer for the kappa opioid receptor. J Nucl Med 56:243–248. https://doi.org/10.2967/jnumed.114.147975
Naganawa M et al (2016) Receptor occupancy of the kappa-opioid antagonist LY2456302 measured with positron emission tomography and the novel radiotracer 11C-LY2795050. J Pharmacol Exp Ther 356:260–266. https://doi.org/10.1124/jpet.115.229278
Nicolas JM et al (2016) Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 57:201–209. https://doi.org/10.1111/epi.13267
Normandin MD et al (2015) Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test–retest reproducibility, and gender differences. J Cereb Blood Flow Metab 35:1313–1322. https://doi.org/10.1038/jcbfm.2015.46
Normandin MD, Koeppe RA, Morris ED (2012) Selection of weighting factors for quantification of PET radioligand binding using simplified reference tissue models with noisy input functions. Phys Med Biol 57:609–629. https://doi.org/10.1088/0031-9155/57/3/609
Ogden RT (2003) Estimation of kinetic parameters in graphical analysis of PET imaging data. Stat Med 22:3557–3568. https://doi.org/10.1002/sim.1562
Park E et al (2015) Test-retest reproducibility of the metabotropic glutamate receptor 5 ligand [(18)F]FPEB with bolus plus constant infusion in humans. Eur J Nucl Med Mol Imaging 42:1530–1541. https://doi.org/10.1007/s00259-015-3094-6
Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3:1–7. https://doi.org/10.1038/jcbfm.1983.1
Salinas C et al (2013) Kinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis. J Cereb Blood Flow Metab 33:700–707. https://doi.org/10.1038/jcbfm.2012.208
Saricicek A et al (2015) Test–retest reliability of the novel 5-HT1B receptor PET radioligand [11C]P943. Eur J Nucl Med Mol Imaging 42:468–477. https://doi.org/10.1007/s00259-014-2958-5
Sawant-Basak A et al (2017) Quantitative projection of human brain penetration of the H3 antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy. Xenobiotica 47:119–126. https://doi.org/10.3109/00498254.2016.1166531
Slifstein M, Laruelle M (2000) Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med 41:2083–2088
Smith JA et al (2015) Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. https://doi.org/10.1093/ijnp/pyu027
Talbot PS et al (2005) \(^{11}\)C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons. J Nucl Med 46:484–494
Xia Y et al (2015) Measurement of Bmax and Kd with the glycine transporter 1 radiotracer (1)(8)F-MK6577 using a novel multi-infusion paradigm. J Cereb Blood Flow Metab 35:2001–2009. https://doi.org/10.1038/jcbfm.2015.163
Yaqub M, Boellaard R, Kropholler MA, Lammertsma AA (2006) Optimization algorithms and weighting factors for analysis of dynamic PET studies. Phys Med Biol 51:4217–4232. https://doi.org/10.1088/0031-9155/51/17/007
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Naganawa, M., Gallezot, JD., Rossano, S. et al. Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy. Bull Math Biol 81, 3508–3541 (2019). https://doi.org/10.1007/s11538-017-0374-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11538-017-0374-2